Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck

NCT02061631 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: Cisplatin
DRUG: DOCETAXEL XRP6976
DRUG: Dexamethasone
DRUG: Dexamethasone

Sponsor

Sanofi